Esomeprazole News and Research

RSS

Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

$FDA warns on possible fracture risk with proton pump inhibitors use$

FDA warns on possible fracture risk with proton pump inhibitors use

The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk.

26 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

DIS serves as marker for new methods to diagnose NERD

Gastroesophageal reflux disease is an important public health problem which is extremely common nowadays. Symptoms of GERD arise from the exposure of increased acid gastric contents into the lower part of the esophageal mucosa. Most patients with GERD have NERD with invisible mucosal damages under endoscopy.

31 Mar 2010

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.

16 Mar 2010

POZEN reports net loss of $6.9M for year ended December 31, 2009

POZEN Inc., today announced results for the fourth quarter and year ended December 31, 2009.

3 Mar 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Teva Pharmaceutical Industries Ltd. announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.

7 Jan 2010

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

Patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC (omeprazole) with the anti-clotting drug Plavix (clopidogrel), the U.S. Food and Drug Administration warned on Nov. 17.

19 Nov 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

POZEN announces Phase I study results of PA65020

POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

28 Oct 2009

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

20 Oct 2009

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

31 Aug 2009

Radiofrequency ablation eradicates problems in most patients with Barrett's esophagus

A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress.

27 May 2009

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

PPI prescribed for asthma ineffective and too expensive

According to researchers in the U.S. millions of asthma patients taking the drug Nexium, (esomeprazole), or a similar drug are doing so unnecessarily.

13 Apr 2009

Treatment for acid reflux does not improve asthma symptoms

A commonly used treatment for acid reflux does not improve asthma symptoms or control in patients who do not have symptoms of gastroesophageal reflux (GER), according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and by the American Lung Association (ALA).

12 Apr 2009